1. Home
  2. LINC vs TBPH Comparison

LINC vs TBPH Comparison

Compare LINC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lincoln Educational Services Corporation

LINC

Lincoln Educational Services Corporation

HOLD

Current Price

$25.64

Market Cap

949.7M

Sector

Real Estate

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.08

Market Cap

908.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LINC
TBPH
Founded
1946
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
949.7M
908.9M
IPO Year
2005
2013

Fundamental Metrics

Financial Performance
Metric
LINC
TBPH
Price
$25.64
$17.08
Analyst Decision
Strong Buy
Buy
Analyst Count
4
6
Target Price
$45.00
$18.40
AVG Volume (30 Days)
1.3M
390.5K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
279.13
EPS
0.20
N/A
Revenue
$261,853,000.00
$15,386,000.00
Revenue This Year
$15.16
$8.46
Revenue Next Year
$9.02
N/A
P/E Ratio
$128.78
N/A
Revenue Growth
32.98
N/A
52 Week Low
$17.29
$13.08
52 Week High
$56.34
$21.03

Technical Indicators

Market Signals
Indicator
LINC
TBPH
Relative Strength Index (RSI) 29.24 65.18
Support Level $25.27 $16.80
Resistance Level $28.00 $17.11
Average True Range (ATR) 1.50 0.05
MACD 0.43 0.01
Stochastic Oscillator 27.67 89.19

Price Performance

Historical Comparison
LINC
TBPH

About LINC Lincoln Educational Services Corporation

Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: